ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: March 12, 2023

ClinicalTrials.gov ID: [Not yet assigned]

Study Identification

Unique Protocol ID:	DEUNTAVIOUS DECOREY ARNOLD 01
Brief Title:	Psilocybin (Psychedelic Mushrooms) Use to Cure Chronic and Terminal Illness (DDA XONJX Can)
Official Title:	DEUNTAVIOUS DECOREY ARNOLD (Psychedelic Mushrooms) 01 GT vs Cancer
Secondary IDs:	7692-01 [By Order of New Jerusalem X O.F.M. Ltd. Co]

Study Status

Record Verification:	March 2023
Expanded Access Status:	Available

Sponsor/Collaborators

Sponsor:	By Order of New Jerusalem X WM OFM
Responsible Party:	Sponsor
Collaborators:	

Oversight

U.S. FDA IND/IDE:	No

Study Description

Brief Summary:	Clinical potential of psilocybin as a treatment for mental health conditions, chronic pain, Treatment for cancer, use in Assisted Therapy in Medicine, Therapeutic Potential, and cure to any incurable terminal illness known to man.
Detailed Description:	Classic psychedelic (serotonergic) drugs interact with the serotonin receptors (5-HT/5- hydroxytryptamine receptors) and their subtypes densely located within the brain [7–9]. These receptors mediate emotions and moods such as anxiety and aggression, cognition, sex, learning memory, appetite along with other biological, neurological and neuropsychiatric processes. These 5-HT receptors are also located in the central and peripheral nervous systems. Serotonin receptors are the target of multiple recreational and pharmaceutical drugs such as hallucinogens, empathogens, antipsychotics, antidepressants, antiemetics, antimigraine agents and anorectics.

Conditions

Conditions: Mental Disorder
Cancer
COVID-19
Add Attention Deficit Disorder
Pain, Chronic
Terminal Illness
Post Traumatic Stress Disorder
Anxiety Disorders
Depressive Disorder
Asthma
Joint Diseases

Keywords: mycology
PREP Act
Clinical Trails
psilocybin

Study Design

Study Type: Expanded Access
Individual Patients
Treatment IND/Protocol

Interventions

Interventions Dietary Supplement: DEUNTAVIOUS DECOREY ARNOLD
Other Names:
XONJX
MOST HIGH
A cross genetics strand of mycelium, from medical and psychedelic fungi infused with multiple vitamins and minerals

Eligibility

Minimum Age: 21 Years

Maximum Age: 75 Years

Sex: All

Gender Based: No

Criteria: Inclusion Criteria:

- Diagnosed with a chorionic or terminal illness or disease in mid or late stages

Exclusion Criteria:

- minors

Contacts/Locations

Central Contact Person: Chief Information Officer
Telephone: 817-650-3523

Email: cio@xonjx.org

Central Contact Backup: Chief Compliance Officer
Telephone: 678-886-3271
Email: media@xonjx.org

Study Officials:

Locations: **United States, Texas**
By Order of New Jerusalem X O.F.M. Ltd. Co.
Houston, Texas, United States, 77026
Contact: Chief Information Officer 817-650-3523 cio@xonjx.org
Contact: Chief Compliance Officer 678-886-3271 media@xonjx.org

References

Citations:

Links: